Takeda 1H FY18 (YE Mar'19) Results - First Glance
Key highlights Notwithstanding brisk contribution by the key growth drivers including Entyvio (+33% to ~¥129b), Ninlaro (+36% to ~¥30b), Takecab...
813 Views
As Expected, USFDA Approves Hemlibra for Hemophilia A in Patients Without Inhibitors
Non-inhibitor patients constitute ~80-90% of the total hemophilia A population size Consequently, Hemlibra’s (emicizumab, in-house, US Launch -Nov...
335 Views
Takeda/Shire III : EGM Announced, Drug Deal Coming Together
Friday after the close, Takeda Pharmaceutical (4502 JP) announced that the company had established the Record Date for its EGM to approve its...
1.3k Views
Pessimism Overdone: Takeda Undervalued By 40% Under Modestly Enhanced Post-Deal Financial Assumption
Takeda Pharmaceutical Co Ltd (4502 JP)’s CMP highly underappreciates potential financial transformation through its integration with Shire and the...
496 Views
Takeda/Shire II: Drugs, Divvies, and AGM Votes
In Takeda/Shire I : On Drug Deals and Deckchairs I discussed the Drug Deal (the terms to the deal) and the Deckchairs - the significant reshuffling...
358 Views